![]() |
WebMD Health Corp. 111 Eighth Avenue 7th Floor New York, NY 10011 212.624.3700 Phone |
Re: | WebMD Health Corp. Form 10-K for the Year Ended December 31, 2010 Filed March 1, 2011 File No. 0-51547 |
1. | Tell us what consideration you gave to disclosing the factors that you used to identify reportable segments, including the basis of organization (e.g., products and services, geographic areas, etc.), and whether operating segments have been aggregated. As part of your response, tell us what factors you considered in determining that public and private on-line portals should be presented as one segment. Further, tell us what consideration you gave to disclosing the entity-wide information required by ASC 280-10-50-38 through 42. |
a) | It engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same public entity). | ||
b) | Its operating results are regularly reviewed by the public entitys chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. | ||
c) | Its discrete financial information is available. |
| Information about Products and Services As referred to above, the Company has included disclosures on pages 72-74 of the Companys 2010 Form 10-K regarding the revenue generated by its public portals and private portals which represent its two primary groups of services. In future filings on Form 10-K the Company will also include this revenue disclosure within the notes to the financial statements. | ||
| Information about Geographic Areas On page F-15 of the Companys 2010 Form 10-K, the Company disclosed that its revenue is principally generated in the United States and disclosed the amount of revenue derived from customers outside the United States, which was approximately 1.2% of revenues in 2010. | ||
| Information about Major Customers On page F-15 of the Companys 2010 Form 10-K, the Company disclosed that none of its customers accounted for 10% or more of its revenues. | ||
2. | Tell us what consideration you gave to disclosing your accounting policy for recording and disclosing loss contingencies. You should describe how your policy is applied to pending or threaten contingencies and commitments including unasserted claims that are probable of being asserted. See ASC 450-20. In addition, tell us whether you are offsetting any contingency accrual against an insurance receivable. If so, please explain why the offset is appropriate and identify the literature that supports your accounting. |
3. | We note your disclosure that you have recorded an accrual for indemnity obligations relating to the EPS sale based on the Companys estimate of the low end of the range of probable costs. If the there is a reasonable possibility that a loss exceeding amounts already recognized may have been incurred, and the amount of that additional loss would be material, you must disclose either an estimate of the possible loss, or range of loss, or a statement that such an estimate cannot be made or that such amounts are not material to the financial statements. Please tell us whether you believe that it is reasonably possible that additional losses would be material and, if so, how your disclosures comply with paragraphs 3 through 5 of ASC 450-20-50 and SAB Topic 5Y. |
4. | We note your disclosures regarding various contingencies, both general and specific. If there is at least a reasonable possibility that a loss exceeding amounts already recognized may have been incurred, you must either disclose an estimate of the additional loss or range of loss, or state that |
such an estimate cannot be made or, if true, state that the reasonable possible loss in excess of the amount accrued is not material with respect to your financial statements as a whole. Please refer to ASC 450-20-50 and Interpretive Response to Question 2 of SAB Topic 5Y. |
| the Company is responsible for the adequacy and accuracy of the disclosure in the filing; | ||
| the Staffs comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and | ||
| the Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
cc: | Wayne Gattinella, Chief Executive Officer Stephen Giove, Shearman & Sterling LLP |
/4!$0-%,3P00PQ%,%#`N#QT1T##4UPQX8>)D#'AARVZ&*+=_!``41* M)C0PIDM<'$'?!P)0J)-%,S@0PLH;'#'`A[D\<"> M>];1`I\/^)"#%D*P\0$%?!2Q@18E@"1($)OPL88>$M`0`0T=D%!!$&&PTXD; MBPTP#UENK,%"``@@T$$(K(ER2R=KP!``#IB"&=X?$Q210QU[YK&`$\[XX0PH M$RECHA/-&=;9`"<4H% M$!1P*09Z,`%I%EF\X\`.`#@0S3/OZ(&!J@9T`9:K)%JF!Q1`6G!$F"T)<@&T M?Z+P`@]Z,>`>41,IH:?_L@]SP\6?=>@PP@@EI+#`$T+,X($//NQQ)A.%# M'2AXL0$;,AKW1RZWU"$0'@?(`+5#!P@A\UK!$"%#@@8``8G_S!HQMC%+"$ M%8Q18ODMA0V@+PT%[&!*9*0Q0(<'*'",P@P\]"&Q7*DT9,(3=R?[P,.O;?#G M`VA,8Q%%#"10@A:ZYS$X3)O,(*MR3@I`4TT'!`%34H;D0-%0`0`0X12``' M_Q,TF;`&%!$4P$(T/-]"UC%&_"#`$E.(X(9_?RE^PNI^HJ!L#@O8R&DFLI$; M:,$';=#=PT"Q@63E00B@``(VRM,0)SQ!![QJ@0\48)&%_*$?0>`#$`;@``NL MJUV<$H4-,/"%"$0``R%P`^WX<(,(?*$#>I@(SWBA$;E080=)L`,&;."&*)P@ M?T%@P,*B=:8-T$$HR``+$-C`*SVU(`\+Y(/O'M`")8!B`H-)1HDNH(1IM:&+ MUGC3'Y(8AB@$80!2X(4_Z4`!D-GBLL:QD%@^PPE*:!VW M4N#!#\8B>PRHP"\CD`81R"`=8"`!$@*P`P-\H0!G>"83)N"`#B`@#38`0Q5V M$(`A0`$*`DCF'7I4@"1@0`0A.$,`.H"'`HA!`U:PP26Y.`(E\*H-7G@"`R2( MC0]P`04Y2`$;^LDM!1RC@7O_\D!##P&$!60P!R,HQ"UB<0LF>"\"`E#!"H`0 M!AL<8`D&J`(+(I"$H$9!(YGK@00J8`,`[-0`1W#K$A"P@PJ8`0$9D(`>#-"! M,V"!!&88@AJFP((EMJ`$NCI3'G1P@W/0901>V`,:Z*``JFK!JG_`Z@.TNH@) M*,!/#\A#\`B1$K+RZ*P"^,$5@``"%@Q6!'P0@0:2T``1D.$44^L!#*H```&D M`0`4J,$$K+"$TO45`5.0```L`%@7K`$,'$`"$@PP5!0T:@1Y\$'KGF`;>")5 M`4!(@6E1JUK6*H(//-`DKS9@BT'PT!8D`F(2 ]*I_LFP@_7*`.=ZL#?R7VJ/G(+@@F MP,)P-<""/JP!"TL0@+U64`4.:&`.`.!1$02@`0B4X:T8*(,;@+""'\C!#@=P MP!$$8(<,3&$'+G#!)01A`"2H`0-+],$"0,0&'^CI@7^X9`N\D()Q_+BJ0L[J M5@V1*-CZ0`E(^4,G-L*`N_Y@"AG(P`[`H(<:`/,K@"'`"0!`U(@`A=,*$` MQL"!C^+9P&,80AP"\`,XD"#42+#"U2A`A"ATXJT:X,#J8O^[@-? )6+.BA!(3KAD#!0X=,9$`,`*@"#`J1A#!Q9`1$@ M$.H#4,`&'4`K#(;P!2B$H`)@:$(:\#`$&'2!"$WX:0!8P(2K1,'8%0@`_2!` MAWB*^P_&0VKK=&`F'SP!"*^9*I#IR^U%).`)>,N#%E)0"++8`B5^0+<&`!"" M'YDADGS80AA(4-,`D"!=-.``!RS%3@/LM`%-<(`+P`"#* N`:KQ:`JPG
, M[3`<,<)_5#`%)"0;`FE(0XJ%LX7_((@@`.3<`0>2D`8(8"`).$B#B0%`@A#` MP3-=6/P<;KH&>&6!$R%`<`$`X((7MV`!%BH!`C-9!P`R3RZE]9,.4K"142:K M[509C$V:DD\^EG`>0@:^)(8YO$$% M1X`#8_A0`QF`P0P8$$-BX=`I5WP7`A&0@L&8\.('_+XF%.!"M/=DR[_T0;Y^ M`J`$&[BR80S+(N1Q!UP0*!US;9,F?"?0!R%P`'XG`)''`@=A"@P0!!4P378P M!1J@`08@`M4G!R[P#MZ5`-Q1 S)A"XTE=2 M$`$&,#Y@H'7N1PA'.$JG]`$[J`P*0$_24@+8L$4M\`*O9`)$P1%.P`,;D`-Y MX" <"9/,#;1D`PIL`%H4`).0#N" MD`*`F%3&$(0/H`,?T%D1=`,?4`)RPBN,<@-0U'*L`!<:`^D^`'#H`%#5!. M90`]G1`#]%0':-!CU4`B?$`!3@`6EF,1-G@F/B`$UJ!V*-`&.Z8$)1"2):`$ M7+"0.<`%;$`;>#$SG(9(:"@!2V`'#0`F$[`%H5`#9/!&`V,'<%8&RS$UZ6,! M5F`%'9``!>08!'5``'!`"IVAT#1!4%8`+%/`!([`M=:`%;$"-PH(,2H$7 M$:D`&S`G9_("*7`#:/"(#Z`RK9-`K)<'.?`"(U`$8D,3W>8F`]`%!I`J.X!S MM,4C>LF7_@($,"`!+I2!`M``$G`$P='_(V<@`-G%`0<0E5@`!Z?0"CSP!"^@ M!9RI`VCP`<."A\9P##P@!)QYFEJ`!D4@EM7B`=5B+5K@`1[P`L=(!TT!&8N` M$BEA`F`@`CNP`PXP`+CY![I)'&`0`K]9!6YP"VO@`&9`+P#``GK@`J`Q`50P M`7)%+[^I`E7`&-.1$DYP!T7@+1]0!#&`*";'`^4YGN5Y!Q20`!?`(A\PG]X2 M`SQP`S1"&XR@FT=D`M91`<*Y!5D@"/RI::!2`9S&`%>P!2]1"B.5#P\E(/"P M',%!%I"QA8@T%X0QB ?`H,2IF[C2 MF)SF"B2A%4JR\!U4D*,Y&@P?`0*WH!*6XT;N(0VH41$KF1"Z%Q-%>@PDZ@U( M&AB-0")RH1+Z\Q]_L1&R0YQD(*"YD`KO8Z&G8`(H(:!1\*-E^BA!T!XE>@C# M &P0A@^C[%,HR;EJ<<40.WF22!0P6S@!H6.D(A>@I0 M1@Q,YCX4$1=%)A,QL0RT0S%U*AM%V`AY*D##HQ%]"J9YL1>GP'T!&1U..!Z; MFB3"B0U4"CIX=PW'L!?N,0ST\!JV43P&-0P8<9=_41L*41O`ZJ:UL`W(41LO ;<1YQ03OU0*M/Z@@X$:>V\7:S&AAQRJN!```[ ` end